About
Lipum AB is a clinical-stage biotech company developing SOL-116, a humanized antibody with a novel anti-inflammatory mechanism for treatment of chronic inflammatory diseases such as rheumatoid arthritis; the company has completed a First-in-Human Phase 1 study.
Explore Lipum AB's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.